Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo
about
Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivoLipid phosphate phosphatase (LPP3) and vascular developmentRole of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapyLipid phosphate phosphatases and their roles in mammalian physiology and pathologyRegulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphateLysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrestAnalysis of the membrane proteome of ciprofloxacin-resistant macrophages by stable isotope labeling with amino acids in cell culture (SILAC)Lysophosphatidic acid counteracts glucagon-induced hepatocyte glucose production via STAT3.Sphingosine Kinase 2 Inhibition and Blood Sphingosine 1-Phosphate Levels.Decreased peritoneal ovarian cancer growth in mice lacking expression of lipid phosphate phosphohydrolase 1.Noise-induced cochlear F-actin depolymerization is mediated via ROCK2/p-ERM signalingMechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice.Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate.Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.Dysregulation of lysophosphatidic acids in multiple sclerosis and autoimmune encephalomyelitis.The effects of EPA, DHA, and aspirin ingestion on plasma lysophospholipids and autotaxin.Comparison of muscle transcriptome between pigs with divergent meat quality phenotypes identifies genes related to muscle metabolism and structureLysophosphatidic acid in atherosclerotic diseasesLipid phosphate phosphatase inhibitors locally amplify lysophosphatidic acid LPA1 receptor signalling in rat brain cryosections without affecting global LPA degradationBinding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells.Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distributionLysophospholipid mediators in the vasculatureLC-MS based metabolomics identification of novel biomarkers of tobacco smoke-induced chronic bronchitis.Lipid phosphate phosphatase-1 expression in cancer cells attenuates tumor growth and metastasis in mice.Lysophosphatidic acid (LPA) and its receptors: role in airway inflammation and remodeling.Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progressionAutotaxin through lysophosphatidic acid stimulates polarization, motility, and transendothelial migration of naive T cellsThe combination of EPA+DHA and low-dose aspirin ingestion reduces platelet function acutely whereas each alone may not in healthy humans.Tetracyclines increase lipid phosphate phosphatase expression on plasma membranes and turnover of plasma lysophosphatidate.Lipid phosphate phosphatases and signaling.Rapid and reversible enhancement of blood-brain barrier permeability using lysophosphatidic acid.The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation.The effects of aspirin and fish oil consumption on lysophosphatidylcholines and lysophosphatidic acids and their correlates with platelet aggregation in adults with diabetes mellitus.Blood relatives: dynamic regulation of bioactive lysophosphatidic acid and sphingosine-1-phosphate metabolism in the circulation.Arguing the case for the autotaxin-lysophosphatidic acid-lipid phosphate phosphatase 3-signaling nexus in the development and complications of atherosclerosis.Liver-specific deletion of the Plpp3 gene alters plasma lipid composition and worsens atherosclerosis in apoE-/- mice.Association between PPAP2B gene polymorphisms and coronary heart disease susceptibility in Chinese Han males and femalesMice with targeted inactivation of ppap2b in endothelial and hematopoietic cells display enhanced vascular inflammation and permeability.The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer.Lysophosphatidic acid as a lipid mediator with multiple biological actions.
P2860
Q26741062-5E4FF9C3-67D9-451F-A032-414243997C21Q27002640-67BFFF58-CFEE-4D98-A2DE-EAB0242AEBF8Q27015257-F0B514CB-832C-45BC-B1BB-01DFB75A060BQ28088430-E42E53B2-2B62-46AC-A22B-6C4F0C4E0B3AQ28260852-30EDA747-DC85-4415-88A7-1BDFD45CA972Q28478339-25025AD3-77FD-41B5-8F9D-C40DBDDE4A23Q28487758-2F85707E-957F-4AA7-B514-F857A08B29D7Q30253010-9FC7AD8E-E7C5-4A6E-A151-5D8FC02B53CAQ30278904-40B795BC-BE20-4A24-AEEC-FF9E5EAAB1AAQ30300375-F3CD0850-6C14-4548-9333-38FA31476B56Q30382426-27CA1E24-EC41-40A8-BA7D-9DA03DCB12FDQ30410474-C02ED2CA-E76C-4C8D-9FE0-203F91B57C64Q30423337-AE13444F-EA57-47AC-BC55-488DCF795E43Q33548625-F3C9A6F0-53AE-41B9-A69C-FB1A83EFD0EAQ33759830-B92A1A95-1DF3-4AA8-913D-6046D6B4823EQ34080568-02133473-74B0-461A-A7F0-F8599C7A36B1Q34217490-E29A0A61-BE57-47FD-BFF8-6125DAD2E817Q34273486-00554F6C-00B1-4786-8DE0-0F67B19AC242Q34300049-2ED07853-A1FE-4377-B509-2BCA3CB411E6Q35266443-E23D127F-4FA1-4CE7-AB1C-888FA0E0E3D7Q35314358-3D66E598-AA28-4F94-9E50-3A0D343D664DQ35533485-D9B23919-6EDA-403B-9ABA-1060E34E9E87Q35781857-C3E49804-ACD0-4C94-A83D-2D6E6CD59D87Q36196845-E56C6B0F-7FA5-4813-8B19-339AF55EDE2CQ36377195-7E5C413B-1F19-49A1-A785-D8B144C6916BQ36399256-FCA83247-3BBD-431E-9DD2-795C2906AB5CQ36431033-B3C76AEE-7FAF-4ACB-BA76-D598470038C3Q36659192-14D18C99-2481-4CB5-A7EC-0169F95C1BFAQ36731751-9D710E48-4654-452F-BA78-1250DBF05439Q37173179-66569464-2F47-455A-924A-E0FD52ABE34CQ37365650-675769F2-A3DE-49C6-80BE-099B061E0677Q37527792-A1DCF4F0-5F55-4085-9CBC-5166899F5751Q37612293-610DC9B0-9D49-4777-95F8-9547CD98D2DEQ37612339-94D0CA2C-76FE-4D1B-996A-CAE55A062FB7Q37620329-26751431-226B-4D85-B691-6F0642982A27Q37698833-9AF58201-B1C2-432B-8605-C4344108F46FQ37706568-F660F567-F445-4860-9565-9845D58077EDQ37727231-F7D6FC43-05D3-4999-8B99-0DB09E0A040AQ38246634-BB6F87CA-071E-4DC3-A65D-63076F66A8C3Q38286968-6A77858F-D930-4E60-9334-3D39C1B5576E
P2860
Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Lipid phosphate phosphohydrola ...... lysophosphatidic acid in vivo
@ast
Lipid phosphate phosphohydrola ...... lysophosphatidic acid in vivo
@en
type
label
Lipid phosphate phosphohydrola ...... lysophosphatidic acid in vivo
@ast
Lipid phosphate phosphohydrola ...... lysophosphatidic acid in vivo
@en
prefLabel
Lipid phosphate phosphohydrola ...... lysophosphatidic acid in vivo
@ast
Lipid phosphate phosphohydrola ...... lysophosphatidic acid in vivo
@en
P2093
P2860
P356
P1433
P1476
Lipid phosphate phosphohydrola ...... lysophosphatidic acid in vivo
@en
P2093
Anastasia Skobeleva
Ashley H Snyder
Chifundo Mataya
David N Brindley
Evgeny V Berdyshev
Jose L Tomsig
Kevin R Lynch
Viswanathan Natarajan
P2860
P304
P356
10.1042/BJ20081888
P407
P577
2009-05-01T00:00:00Z